DRG Instruments Unveils Groundbreaking TBI Test Panel at MEDLAB in Dubai

DRG Instruments Unveils Innovative TBI Test Panel at MEDLAB in Dubai

DRG Instruments GmbH, a key player in immunoassays for over five decades, has launched a groundbreaking test panel designed for evaluating traumatic brain injuries (TBI). At the MEDLAB Middle East conference in Dubai, which runs from February 3 to 6, 2025, the new tests will be showcased alongside the company’s commitment to enhancing healthcare solutions with speed and accuracy.

The new test panel combines GFAP (Glial Fibrillary Acidic Protein) and UCH-L1 (Ubiquitin C-terminal hydrolase L1) assays. These CLIA-automated tests are crafted for use on DRG's proprietary DxDATA™ platform, allowing healthcare providers to assess blood levels of GFAP and UCH-L1 in just 30 minutes. This rapid evaluation is particularly critical as it aids in diagnosing potential TBI within a critical time frame—12 hours post-injury.

Joerg Schloesser, the General Manager and Vice President of Sales at DRG, expressed excitement about the global market introduction of these innovative solutions. He emphasized that the automated testing and fast response times can significantly empower health professionals to make timely and well-informed decisions. “Our goal is to enhance patient care for those affected by traumatic brain injuries worldwide,” Schloesser said.

The panel has been certified with the CE mark, confirming its compliance with Clinical and Laboratory Standards Institute (CLSI) requirements. Additionally, it is meant for use in clinical laboratory settings and is suitable for patients aged 18 and older.

The presentation at MEDLAB will allow attendees to engage directly with the product development team to discuss potential applications and benefits of the new TBI tests. Interested parties are encouraged to reach out directly to DRG for further details or to inquire about regional availability of the testing solutions.

DRG Instruments GmbH originated in 1973 and is headquartered in Marburg, Germany. Since 1990, the firm has been dedicated to developing innovative immunoassays, cultivating partnerships with distributors across 120 countries. The company is recognized for its fully automated DRGHYBRiD-XL® analyzer, which serves both immunoassay and clinical chemistry needs. DRG operates under ISO 13485 certification and adheres to quality system regulations as stipulated by the FDA.

For further inquiries, please contact their sales representative or email info@drg-diagnostics.de.

As the landscape of medical diagnostics continues to evolve, DRG’s commitment to advancing technology reflects a broader trend in the healthcare sector where rapid and accurate testing is crucial for improving patient outcomes—especially in critical situations like traumatic brain injuries. By integrating innovative diagnostic technologies, DRG Instruments is set to impact the standard of care, helping healthcare professionals around the globe deliver timely interventions.

With the imminent launch of this TBI test panel, DRG Instruments stands at the forefront of transforming trauma care, promising a new era of speed and efficiency in medical diagnostics.